Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX6R0H)

Drug Name

5-phenylamino-4-cyano-3-hydroxy-isothiazole Drug Info

Synonyms

CHEMBL209793; 1137-65-1; 4-Isothiazolecarbonitrile, 2,3-dihydro-3-oxo-5-(phenylamino)-; AC1MBJGN; Maybridge4_002946; 5-phenylamino-4-cyano-3-hydroxy-isothiazole; 5-anilino-3-oxo-1,2-thiazole-4-carbonitrile; Oprea1_090337; MLS000850692; SCHEMBL3527060; CTK0G1139; DTXSID30369410; CHEBI:107126; MolPort-002-913-499; GHXPCAXQBVCFNU-UHFFFAOYSA-N; HMS2799B08; HMS1529F20; CCG-1976; ZINC15924361; BDBM50187849; AKOS022652528; AKOS030549246; MCULE-9694822584; NCGC00176381-01; SMR000456709; 5-anilino-3-oxo-isothiazole-4-carbonitrile

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 2726555
ChEBI ID: CHEBI:107126
CAS Number: CAS 1137-65-1
TTD Drug ID: DMX6R0H

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ERK activator kinase 1 (MEK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selumetinib	DMC7W6R	Neurofibromatosis type 1	LD2D.10	Phase 3	[2]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[3]
Pyridic ketone derivative 1	DM3GU7K	N. A.	N. A.	Patented	[4]
RDEA-436	DM0ILRU	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[6]
DEBROMOHYMENIALDISINE	DMDLER8	Discovery agent	N.A.	Investigative	[7]
REVERSINE	DMWDNOK	Discovery agent	N.A.	Investigative	[8]
OROIDIN	DMA2DQT	Discovery agent	N.A.	Investigative	[7]
PD98059	DMZC90M	Cardiac arrest	MC82	Investigative	[9]
4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide	DMDM9UV	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ERK activator kinase 1 (MEK1)	TTIDAPM	MP2K1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
4	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.
5	Clinical pipeline report, company report or official report of MedKoo Biosciences.
6	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
7	Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
8	Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
9	The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9.